Nocion Therapeutics has dosed the first 10 subjects in a Phase 2a study of NOC-100, an inhaled formulation of its NTX-1175, a charged sodium channel blocker, the company said. Nocion is developing NTX-1175 for the treatment of chronic and acute cough, including cough resulting from COVID-19. According to the company, a Phase 1 study of inhaled NTX-1175 was completed earlier this year, and the program has been granted COVID-19-related priority review status in the UK and Germany.
The first part of the Phase 2a study is expected to enroll approximately 40 patients with chronic cough and will evaluate 3 dose levels of nebulized NOC-100 (1, 3, and 10 mg) versus placebo. The second part of the study will evaluate the inhaled NTX-1175 in patients with acute cough.
Lead researcher Jacky Smith of the University of Manchester said, “Long-term chronic cough can have a huge negative impact on someone’s life, which can include anxiety, depression and exhaustion. When inhaled, NTX-1175 may be able to mitigate cough by directly targeting and reducing the activation of the sensory nerves in airways, which represents a unique approach to tackling the problem of cough in general, including chronic cough.”
Nocion CEO Richard Batycky commented, “We are excited to begin this study, which is the first randomized, controlled study of NTX-1175 in the chronic cough population and will help us assess the safety and efficacy of our nociceptor-targeted treatments. We believe that our unique pharmacology, with broad antitussive potential, may be highly differentiated from currently available and investigational approaches, and may improve the lives of chronic cough patients.”
Read the Nocion Therapeutics press release.
